Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEOGENOMICS, INC.

(NEO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NeoGenomics : Shares Rise After Raymond James Upgrade

10/14/2021 | 01:49pm EST


© MT Newswires 2021
All news about NEOGENOMICS, INC.
11/10NEOGENOMICS INC : Change in Directors or Principal Officers (form 8-K)
AQ
11/10NeoGenomics, Inc. Appoints William Bonello as Chief Financial Officer, Effective Januar..
CI
11/10NeoGenomics, Inc. Appoints Kathryn Mckenzie as Chief Sustainability and Risk Officer, E..
CI
11/10NeoGenomics, Inc. Appoints Dave Daly to Its Board of Directors
CI
11/10NeoGenomics Appoints Dave Daly to Its Board of Directors
PU
11/08Morgan Stanley Cuts NeoGenomics to Equal-Weight From Overweight, Price Target to $45 Fr..
MT
11/08Genetron Holdings, NeoGenomics to Collaborate to Provide China-Based Medical Research S..
MT
11/08Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Onco..
AQ
11/08Genetron Holdings Limited Establishes Strategic Partnership with NeoGenomics, Inc. to D..
CI
11/05Stephens Adjusts Price Target on NeoGenomics to $53 from $60, Keep Overweight Rating
MT
More news
Analyst Recommendations on NEOGENOMICS, INC.
More recommendations
Financials (USD)
Sales 2021 485 M - -
Net income 2021 0,67 M - -
Net Debt 2021 288 M - -
P/E ratio 2021 -11 006x
Yield 2021 -
Capitalization 4 512 M 4 512 M -
EV / Sales 2021 9,90x
EV / Sales 2022 8,55x
Nbr of Employees 1 700
Free-Float 96,0%
Chart NEOGENOMICS, INC.
Duration : Period :
NeoGenomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEOGENOMICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 36,65 $
Average target price 51,70 $
Spread / Average Target 41,1%
EPS Revisions
Managers and Directors
Mark Mallon Chief Executive Officer & Director
George A. Cardoza President & Chief Operating Officer-Lab Operations
Kathryn B. McKenzie Chief Financial Officer
Lynn A. Tetrault Non-Executive Chairman
Steven A. Ross Chief Information Officer & Vice President
Sector and Competitors